Antibody discovery is being reshaped by two forces: an explosion of novel formats and the growing role of AI across the DBTL loop. But most teams are still running antibody programs on software that hasn’t kept pace with science, leaving data siloed and relationships missing. In this webinar, hosted by… Read More
Antibody discovery is being reshaped by two forces: an explosion of novel formats and the growing role of AI across the DBTL loop. But most teams are still running antibody programs on software that hasn’t kept pace with science, leaving data siloed and relationships missing. In this webinar, hosted by… Read More
Antibody discovery is being reshaped by two forces: an explosion of novel formats and the growing role of AI across the DBTL loop. But most teams are still running antibody programs on software that hasn’t kept pace with science, leaving data siloed and relationships missing. In… Read More
Antibody discovery is being reshaped by two forces: an explosion of novel formats and the growing role of AI across the DBTL loop. But most teams are still running antibody programmes on software that hasn’t kept pace with science, leaving data siloed and relationships missing. In this webinar on 11… Read More
Antibody discovery is being reshaped by two forces: an explosion of novel formats and the growing role of AI across the DBTL loop. But most teams are still running antibody programmes on software that hasn’t kept pace with science, leaving data siloed and relationships missing. In this webinar, hosted by… Read More
Antibody discovery is being reshaped by two forces: an explosion of novel formats and the growing role of AI across the DBTL loop. But most teams are still running antibody programmes on software that hasn’t kept pace with science, leaving data siloed and relationships missing. In this webinar on 11… Read More
Biotechnology company Immutrin has raised £65 ($86.7) million in Series A financing to help fund its lead asset through clinical proof of concept. Immutrin’s lead asset is targeting ATTR cardiomyopathy, a serious and potentially fatal form of amyloidosis. Amyloidosis is a group of rare,… Read More
Discover how to accelerate ADC development with clearer, faster characterisation of charge heterogeneity and size/purity. This eBook explains when to apply advanced icIEF and CE-SDS methods for ADCs and other novel biotherapeutics to accelerate development timelines. Learn:… Read More
VectorY Therapeutics has announced that the first participant has been dosed in its Phase I/II PIONEER-ALS clinical trial of VTx-002 in people with amyotrophic lateral sclerosis (ALS). VTx-002 is a first-in-class vectorised antibody designed to holistically target TDP-43 pathology in ALS recently granted FDA Fast… Read More
Novartis Pharma and SciNeuro Pharmaceuticals have agreed a worldwide licensing and collaboration agreement to advance SciNeuro’s novel amyloid beta targeted antibody programme for the treatment of Alzheimer’s disease. The programme has identified de novo antibody candidates that incorporate SciNeuro’s proprietary blood brain barrier shuttle technology… Read More
Thermal stability testing is essential in biotherapeutic development—ensuring safety, efficacy, and shelf-life. It also helps predict aggregation and guides formulation and storage decisions. Read this eBook to learn: Core techniques used in today’s labs Pros and cons of each method How to choose the right solution for your… Read More